A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome
Slow-channel congenital myasthenic syndrome (CMS) is a rare subtype of CMS caused by dominant “gain of function” mutations in the acetylcholine receptor. Clinically, the cervical and forearm extensor muscles seem to be preferentially weaker; and conventional treatment with anticholinesterases fails to improve symptoms. In contrast, open channel blockers such as fluoxetine and quinidine have been shown to be of benefit. The objectives of our study were to provide further insight into the clinical features of slow-channel CMS and evaluate response to recommended therapy. We carried out a retrospective clinical follow up study of 15 slow-channel CMS patients referred to the Munich CMS Centre. Detailed clinical data were collected by clinicians involved in the care of each patient, with a particular focus on response and tolerability to recommended therapy. Patients varied widely as regard onset of symptoms, severity of disease and mutations involved. Patients received up to four different medications and some had none. Our results strengthen previous reported findings in terms of clinical phenotype variability and the poor response to pyridostigmine. Although treatment with fluoxetine was beneficial in most patients, a number of our patients suffered significant adverse effects that hindered optimum dose titration or led to treatment cessation. Slow-channel CMS is rare and exhibits distinct clinical and genetic characteristics. Our study suggests that fluoxetine, despite being effective in most patients, can be associated with significant side effects, thus reducing treatment effectiveness in clinical practice.
KeywordsCongenital myasthenic syndromes Slow-channel Treatment Fluoxetine Quinidine
The Institute of Genetic Medicine in Newcastle is part of the MRC centre for Neuromuscular Diseases. Newcastle University is the coordinating centre of TREAT-NMD (EC, 6th FP, proposal #036825; www.treat-nmd.eu). JSM receives a fellowship by the Medical Faculty of Newcastle University. VG is a research fellow of the Alexander von Humboldt Foundation. AA is supported by a grant from the Deutsche Forschungsgemeinschaft (Ab 130/2-1).
Conflict of interest
- 1.Abicht A, Stucka R, Karcagi V, Herczegfalvi A, Horvath R, Mortier W, Schara U, Ramaekers V, Jost W, Brunner J, Janssen G, Seidel U, Schlotter B, Muller-Felber W, Pongratz D, Rudel R, Lochmuller H (1999) A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. Neurology 53:1564–1569PubMedGoogle Scholar
- 6.Engel AG, Ohno K, Milone M, Wang HL, Nakano S, Bouzat C, Pruitt JN 2nd, Hutchinson DO, Brengman JM, Bren N, Sieb JP, Sine SM (1996) New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 5:1217–1227PubMedCrossRefGoogle Scholar
- 14.Kinali M, Beeson D, Pitt MC, Jungbluth H, Simonds AK, Aloysius A, Cockerill H, Davis T, Palace J, Manzur AY, Jimenez-Mallebrera C, Sewry C, Muntoni F, Robb SA (2008) Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 201–202:6–12PubMedCrossRefGoogle Scholar
- 15.Mihaylova V, Scola RH, Gervini B, Lorenzoni PJ, Kay CK, Werneck LC, Stucka R, Guergueltcheva V, von der Hagen M, Huebner A, Abicht A, Muller JS, Lochmuller H (2010) Molecular characterisation of congenital myasthenic syndromes in Southern Brazil. J Neurol Neurosurg Psychiatry 81:973–977PubMedCrossRefGoogle Scholar
- 17.Outteryck O, Richard P, Lacour A, Fournier E, Zephir H, Gaudon K, Eymard B, Hantai D, Vermersch P, Stojkovic T (2009) Novel epsilon subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome. J Neurol Neurosurg Psychiatry 80:450–451PubMedCrossRefGoogle Scholar